AAN 2026: Tavapadon post-hoc analysis strengthens its D1/D5 agonist pitch
Tavapadon will enter a competitive but commercially attractive market after a likely regulatory submission following post-hoc data.
Therapy Area
AAN 2026: Head-to-head trial shows superiority of Qulipta for migraine prevention
Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
ESCMID Global 2026: Zelicapavir demonstrates benefits for high-risk adults with RSV
ESCMID Global 2026: Adibelivir emerges as potential disease-modifying therapy for HSV
Immunotherapy in locally advanced HNSCC: is there still room for new agents?
FDA issues complete response letter to Replimune’s RP1 for melanoma
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
